Ben Creelan, MD | Authors


Tumor-Infiltrating Lymphocytes: Rationale for Use in the Treatment of Solid Tumors and Potential Benefits and Drawbacks

November 08, 2022

In the second interview of this series, Ben Creelan, MD, Associate Member at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.